VolitionRx announced the publication of a peer-reviewed paper and editorial highlighting its Nu.Q NETs H3.1 biomarker as an independent predictor of 28-day mortality and need for renal replacement therapy in sepsis patients. This scientific validation significantly strengthens the commercial potential of their diagnostic technology, particularly in the large sepsis market, and could lead to new licensing agreements.
VolitionRx announced the publication of a peer-reviewed paper in 'Critical Care Medicine' validating their Nu.Q NETs H3.1 biomarker as a predictor of mortality and organ dysfunction in sepsis. This is a significant corporate catalyst as it provides strong scientific backing for their diagnostic technology, which is crucial for adoption in the medical community and for securing commercial partnerships. The company explicitly states they are 'advancing several active commercial discussions with significant players in the diagnostic space,' and this publication directly supports their ongoing licensing process. This news is a long-term positive for VNRX, as it enhances the credibility and marketability of their product, potentially leading to increased revenue through licensing and sales. The key opportunity for traders is the potential for future licensing deals and market penetration in the substantial sepsis diagnostic market.